Proof is unlocking CRISPR technology to make powerful molecular testing accessible to everyone.

Feng Zhang, Ph.D.

Co-Founder

  • Portrait of CRISPR pioneer Dr. Feng Zhang in a light blue, button-down shirt, with short black hair and wearing glasses.
  • Portrait of CRISPR pioneer Dr. Omar Abudayyeh in a blue-and-white checkered, button-down shirt with short dark hair.
  • Portrait of CRISPR pioneer Dr. Jonathan Gootenberg in a dark green, button-down shirt, with curly brown hair and arms folded.

Whether it’s managing COVID or another infectious disease, we want to help people get out into their communities to reconnect safely with their friends, families and loved ones.

FENG ZHANG, Ph.D.


Our Story

Necessity is the mother of invention.
This proverb is centuries old, but today, it’s truer than ever. The world is always turning, but in 2020, it swerved.

And we swerved with it.

World-renowned CRISPR diagnostics pioneers Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Dr. Omar Abudayyeh and Dr. Jonathan Gootenberg—both McGovern Institute fellows at MIT—pivoted their focus towards addressing an emergent need: combating the COVID-19 pandemic.

With deep-rooted conviction, Zhang, Gootenberg and Abudayyeh dropped everything to face a global public health crisis head on. These were the humble beginnings of Proof Diagnostics.
...


Combining advanced CRISPR and RT-LAMP technologies in a novel approach, our scientific team is developing a simple, streamlined platform—harnessing the power of molecular diagnostics—that can quickly test for the presence of the SARS-CoV-2 virus, with the goal of delivering it to people everywhere.

Developed for use within clinics, pharmacies, schools, workplaces and eventually homes, our lab-quality test platform is undergoing rigorous product development so that we can provide fast, accurate diagnostics that will help communities take control of their health. We want to transform the anxiety of waiting days for COVID-19 test results into the peace of mind of quickly knowing what steps to take next.

Our first test system designed to detect SARS-CoV-2 is still undergoing investigation, but we hope it will enable us to fulfill our mission of helping restore a degree of normalcy to our world. From there, we aim to transform personalized health and expand our diagnostic platform to detect other diseases, with the goal of providing actionable health information that will allow people to lead better, healthier lives.

Once a research concept, our cutting-edge diagnostics platform is rapidly becoming a reality, and we pledge to stay at the forefront of infectious disease detection.

Because, at Proof, we believe that knowledge is power—and good health is a necessity.

READ MORE 

Our Founders

Our Team

Board of Directors


Matt McIlwain is the Managing Director of Madrona Venture Group where he invests in a broad range of software and data-driven companies with a focus on cloud computing, dataware, intelligent applications and the intersections of innovation (where life science and data science intersect). Before joining Madrona in 2000, Mr. McIlwain was vice president of business process for the Genuine Parts Company (NYSE:GPC). He was also an engagement manager at McKinsey & Company, concentrating on strategy and marketing in technology-driven sectors.

Mr. McIlwain is a board member (and previous chair) of Fred Hutchinson Cancer Research Center and a board member of Washington Policy Center. He has also been named several times to both the list of Top 100 Venture Capitalists by CB Insights and The New York Times and the Forbes Midas list. Matt is a graduate of Dartmouth College and holds an M.B.A. from Harvard Business School and a master’s in Public Policy from Harvard’s Kennedy School of Government.


Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Dr. Knight also serves on the board of directors of Atalanta Therapeutics, Beam Therapeutics (NASDAQ: BEAM), Ensoma, Geneception, Genomics plc, Iora Health, Leyden Labs, Pulmocide and Sana Biotechnology. Prior to joining F-Prime Capital, he held various senior management roles in private and public biotechnology and consulting companies.

Dr. Knight was also a researcher at AT&T Bell Laboratories, the National Institutes of Health and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.

Scientific Advisory Board

Deborah T. Hung

M.D., Ph.D.

Broad Institute of MIT and Harvard

Feng Zhang

Ph.D., Co-Founder

Broad Institute of MIT and Harvard

David Margulies

M.D., Entrepreneur

Former EVP, Chief Scientist and Director,
Cerner Corporation

Investors

Our Partners in Health

We’re proud to receive funding from and/or collaborate with world‑renowned organizations and innovators. Together, we pledge to help improve global public health by staying at the forefront of infectious disease detection.

Aerial view of Proof Diagnostics’ white Proof Lab reader showing a solid ring of LED lights and sitting on a blue background.

Future‑Proofing Our World

Mission‑driven and people‑focused, Proof is building a talented team committed to providing actionable health information so that communities can enjoy better, healthier lives.

Join Our Team